Skip to content
This is an old version of SMMT from 6 days ago (Nov 15, 2026).See the latest version

SMMT

Price
$14.15
Discount category
Pricey
Intrinsic value source
AI estimate
Next earnings
Feb 4, 2027
Next earnings is estimate
Yes
Company name
Summit Therapeutics
Sector
Biotechnology
About
Summit Therapeutics Inc. (SMMT) is an oncology company based in Miami, Florida, with offices in Menlo Park, California, and Oxford, UK. It develops ivonescimab, a bispecific antibody that blocks PD-1 and VEGF. Summit licensed ivonescimab from Akeso Inc. for North America, South America, Europe, the Middle East, Africa and Japan, and it pays Akeso milestones and royalties equal to a low-double-digit percentage of sales. Ivonescimab is approved in China, where Akeso sells it, but no regulator in the territories of Summit has approved it. Summit runs global Phase III studies in lung and colorectal cancer and Phase II and Phase II/III studies in bladder and kidney cancer. It has no revenue. The common stock trades on the Nasdaq in US dollars. Summit files 10-K and 10-Q reports.
Thesis
The price of Summit Therapeutics depends almost fully on the results of ivonescimab in global studies and on decisions of the FDA. The HARMONi study in EGFR-mutated lung cancer met its progression-free survival endpoint, but its primary overall survival analysis was not statistically significant, and the FDA noted that approval in this setting needs a significant survival benefit. The market values the company on the chance that ivonescimab replaces PD-1 drugs in first-line lung cancer, after studies by Akeso in China showed survival benefits against pembrolizumab and other drugs, and after AstraZeneca invested $2.0 billion in October 2026. For the value to rise, three things must be true. The global HARMONi-3 study must show a clear benefit in first-line squamous lung cancer, with the primary analysis after the needed events in Q4 2026. The FDA must approve ivonescimab in at least one setting. Summit must fund its studies without large new share sales. The FDA decision on the HARMONi application, with a goal date of November 14, 2026, and the HARMONi-3 results in 2027 are the next tests. A negative result can remove most of the value.
Valuation
The intrinsic value for Summit Therapeutics is an AI estimate from November 14, 2026. It is not an analyst's value. An AI research agent calculated it from the filings of Summit Therapeutics with the SEC. Summit has no approved product and no revenue, and its value depends on ivonescimab, which it licensed from Akeso Inc. for North America, South America, Europe, the Middle East, Africa and Japan. The method is a risk-adjusted value of ivonescimab in these territories, plus cash and the exercise proceeds of the stock options, divided by the shares, the shares from the convertible preferred stock, the options and the restricted stock units. The value of ivonescimab is peak annual sales, times 3 for the value of the sales after royalties and costs, discounted for 6 years at 10% a year, times the probability of success. The Form 10-Q for the quarter ended September 30, 2026 gives cash and short-term investments of $629.8 million, no debt, and a net loss of $613.5 million for nine months. It says that Summit pays Akeso royalties equal to a low-double-digit percentage of revenue and milestone payments. It says that AstraZeneca bought Class A Convertible Preferred Stock for $2.0 billion on October 5, 2026, convertible into 108,955,369 shares of common stock. It gives 116,798,660 stock options with a weighted average exercise price of $4.21 and 730,000 restricted stock units at September 30, 2026. The cover of the 10-Q gives 799,763,918 shares at October 30, 2026. The estimate thus uses cash of $2,629.8 million, option proceeds of $491.7 million and 1,026.25 million shares, and it ignores the cash used after September 30, 2026, which is an assumption. The Q3 2026 release (8-K, November 4, 2026) gives an FDA goal date of November 14, 2026 for the HARMONi application in EGFR-mutated lung cancer, and it says that the FDA noted that approval needs a statistically significant overall survival benefit, which the primary analysis of HARMONi did not show. The peak sales, the multiple, the discount rate and the probabilities are assumptions. The low case assumes peak sales of $3 billion, mainly in lung cancer after other treatments, with a probability of 35%. It gives $4.77 per share. The base case assumes peak sales of $10 billion, after a positive HARMONi-3 study in first-line lung cancer, with a probability of 55%. It gives $12.12 per share. The high case assumes peak sales of $18 billion, from first-line lung cancer and other tumors such as colorectal and biliary tract cancer, with a probability of 70%. It gives $23.83 per share. The estimate assumes weights of 25%, 50% and 25%. The weighted intrinsic value is $13.21 per share. Summit holds the rights to ivonescimab in its territories, but it depends on one drug from one partner, it has no sales, and large drug companies develop other PD-1 and VEGF bispecific antibodies. As of Nov 14, 2026.
Risks
The FDA noted that approval in EGFR-mutated lung cancer needs a statistically significant overall survival benefit, which the primary analysis of HARMONi did not show. A rejection delays the first sales in the United States. Summit depends on one drug. If HARMONi-3 or HARMONi-7 fail, most of the value of the company can go. Most positive Phase III data come from studies in China that Akeso ran and analyzed. The FDA can give these data less weight, and limits on trade between the United States and China can affect supply from Akeso. Summit lost $613.5 million in the first nine months of 2026 and pays for its studies by selling shares, and stockholders approved 1 billion more authorized shares. New share sales reduce the part of the company that each share owns. Other companies, many with large drug companies as partners, develop PD-1 and VEGF bispecific antibodies, and pembrolizumab with chemotherapy is the standard treatment in first-line lung cancer.
Balance sheet
Cash: $630M Debt: $0.0M Net cash: $630M At September 30, 2026, Summit had cash and cash equivalents of $150.8 million and short-term investments of $479.0 million, or $629.8 million, and no debt. Total liabilities were $128.2 million. On October 5, 2026, Summit received $2.0 billion before issuance costs from AstraZeneca for Class A Convertible Preferred Stock. In Q3 2026 it raised $94.1 million through its at-the-market program, and net cash used in operating activities was $423.2 million in the first nine months of 2026. As of Sep 30, 2026.
Checkpoints
Nov 14, 2026: FDA decision on HARMONi. Pending. Watch: The FDA approves ivonescimab with chemotherapy in EGFR-mutated lung cancer after TKI therapy, and this passes; a complete response letter fails. Feb 4, 2027 (estimate): Q4 2026 results. Pending. Watch: Cash and investments at December 31, 2026 are more than $2 billion with no large new share sale, and this passes; a large new share sale fails. Q1 2027 (estimate): HARMONi-3 squamous cohort results. Pending. Watch: The squamous cohort of HARMONi-3 shows a statistically significant progression-free survival benefit, and this passes; no significant benefit fails. Q2 2027 (estimate): HARMONi-3 non-squamous cohort results. Pending. Watch: The non-squamous cohort of HARMONi-3 shows a statistically significant progression-free survival benefit, and this passes; no significant benefit fails.
Recent events
Nov 4, 2026: Summit reported Q3 2026 results. The net loss was $208.4 million, and cash and short-term investments were $629.8 million at September 30, 2026. Stockholders approved an increase of the authorized common shares from 1 billion to 2 billion. Oct 5, 2026: AstraZeneca completed a $2.0 billion equity investment in Class A Convertible Preferred Stock of Summit, convertible into 108,955,369 shares of common stock. In September and October 2026, Summit also agreed to clinical trial collaborations with AstraZeneca, and with AstraZeneca and Daiichi Sankyo, to test ivonescimab with their antibody-drug conjugates. Sep 15, 2026: Updated HARMONi data at WCLC 2026 showed an overall survival hazard ratio of 0.76 in the global population (nominal p=0.0151) and of 0.76 in western patients, with no new safety signals. Sep 2, 2026: Akeso reported that ivonescimab alone improved overall survival against pembrolizumab alone in the HARMONi-2 study in China, with a hazard ratio of 0.73, in PD-L1-positive lung cancer. Aug 25, 2026: Akeso reported that ivonescimab with chemotherapy improved overall survival against durvalumab with chemotherapy in the HARMONi-GI1 study in biliary tract cancer in China. Aug 5, 2026: Summit started HARMONi-GU1, a global Phase II/III study of ivonescimab with enfortumab vedotin in first-line bladder cancer. Jul 23, 2026: Summit reported Q2 2026 results and agreed with J.P. Morgan Securities LLC to sell up to $380 million of common stock through an at-the-market program. May 30, 2026: Phase II data in first-line colorectal cancer at ASCO 2026 showed an objective response rate of 70.8% for ivonescimab with chemotherapy. Jan 29, 2026: The FDA accepted the application to approve ivonescimab with chemotherapy in EGFR-mutated lung cancer after TKI therapy, with a goal date of November 14, 2026.
See changes